Spyre Therapeutics, Inc.SYRENASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank92
3Y CAGR+176.0%
5Y CAGR+39.5%
Year-over-Year Change
Price-to-book ratio
3Y CAGR
+176.0%/yr
vs -24.4%/yr prior
5Y CAGR
+39.5%/yr
Recent acceleration
Acceleration
+200.4pp
Accelerating
Percentile
P92
Near historical high
vs 5Y Ago
5.3x
Strong expansion
Streak
3 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 15.85 | +649.6% |
| 2024 | 2.11 | +162.1% |
| 2023 | 0.81 | +7.0% |
| 2022 | 0.75 | -79.7% |
| 2021 | 3.72 | +23.9% |
| 2020 | 3.00 | -26.1% |
| 2019 | 4.06 | +75.6% |
| 2018 | 2.31 | +42.3% |
| 2017 | 1.63 | +140.4% |
| 2016 | 0.68 | - |